David Risinger
Stock Analyst at Leerink Partners
(3.57)
# 865
Out of 5,124 analysts
175
Total ratings
65.26%
Success rate
14.39%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $456 → $525 | $453.36 | +15.80% | 6 | Dec 29, 2025 | |
| ROIV Roivant Sciences | Maintains: Outperform | $29 → $32 | $21.70 | +47.47% | 6 | Dec 15, 2025 | |
| XOMA XOMA Royalty | Maintains: Outperform | $58 → $45 | $26.59 | +69.24% | 1 | Dec 11, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Outperform | $886 → $1,104 | $1,074.68 | +2.73% | 17 | Nov 10, 2025 | |
| IMA ImageneBio | Initiates: Outperform | $30 | $6.90 | +334.78% | 1 | Oct 24, 2025 | |
| HALO Halozyme Therapeutics | Upgrades: Market Perform | $70 | $67.30 | +4.01% | 4 | Oct 14, 2025 | |
| JNJ Johnson & Johnson | Downgrades: Market Perform | $169 → $153 | $206.95 | -26.07% | 4 | May 13, 2025 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $762 → $834 | $771.87 | +8.05% | 9 | Feb 5, 2025 | |
| ABBV AbbVie | Upgrades: Outperform | $206 | $228.49 | -9.84% | 7 | Nov 22, 2024 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Outperform | $55 → $73 | $53.94 | +35.34% | 4 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $69 | $20.86 | +230.78% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $12.20 | +31.20% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $30.31 | +45.17% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $106 → $153 | $46.14 | +231.60% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $15 → $10 | $18.71 | -46.55% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $47 | $48.48 | -3.05% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $267 → $318 | $327.31 | -2.84% | 4 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $11 | $25.01 | -56.02% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $122.74 | -25.86% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $24.90 | +92.77% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $7.17 | +416.04% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $170.00 | +3.53% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $12.45 | +28.51% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $13.92 | +223.28% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $6.95 | +403.60% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $22.63 | +81.18% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $125.82 | +38.29% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $38.64 | +31.99% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $31.21 | -74.37% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $105.26 | -15.45% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $12.60 | -76.19% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $27.98 | -42.82% | 9 | Apr 2, 2020 |
Vertex Pharmaceuticals
Dec 29, 2025
Maintains: Outperform
Price Target: $456 → $525
Current: $453.36
Upside: +15.80%
Roivant Sciences
Dec 15, 2025
Maintains: Outperform
Price Target: $29 → $32
Current: $21.70
Upside: +47.47%
XOMA Royalty
Dec 11, 2025
Maintains: Outperform
Price Target: $58 → $45
Current: $26.59
Upside: +69.24%
Eli Lilly and Company
Nov 10, 2025
Upgrades: Outperform
Price Target: $886 → $1,104
Current: $1,074.68
Upside: +2.73%
ImageneBio
Oct 24, 2025
Initiates: Outperform
Price Target: $30
Current: $6.90
Upside: +334.78%
Halozyme Therapeutics
Oct 14, 2025
Upgrades: Market Perform
Price Target: $70
Current: $67.30
Upside: +4.01%
Johnson & Johnson
May 13, 2025
Downgrades: Market Perform
Price Target: $169 → $153
Current: $206.95
Upside: -26.07%
Regeneron Pharmaceuticals
Feb 5, 2025
Upgrades: Outperform
Price Target: $762 → $834
Current: $771.87
Upside: +8.05%
AbbVie
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $228.49
Upside: -9.84%
Bristol-Myers Squibb Company
Nov 12, 2024
Upgrades: Outperform
Price Target: $55 → $73
Current: $53.94
Upside: +35.34%
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $20.86
Upside: +230.78%
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $12.20
Upside: +31.20%
Sep 17, 2024
Initiates: Outperform
Price Target: $44
Current: $30.31
Upside: +45.17%
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $46.14
Upside: +231.60%
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $18.71
Upside: -46.55%
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $48.48
Upside: -3.05%
Oct 11, 2023
Upgrades: Outperform
Price Target: $267 → $318
Current: $327.31
Upside: -2.84%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $25.01
Upside: -56.02%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $122.74
Upside: -25.86%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $24.90
Upside: +92.77%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $7.17
Upside: +416.04%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $170.00
Upside: +3.53%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $12.45
Upside: +28.51%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $13.92
Upside: +223.28%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $6.95
Upside: +403.60%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $22.63
Upside: +81.18%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $125.82
Upside: +38.29%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $38.64
Upside: +31.99%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $31.21
Upside: -74.37%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $105.26
Upside: -15.45%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $12.60
Upside: -76.19%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $27.98
Upside: -42.82%